JPWO2020020790A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020020790A5 JPWO2020020790A5 JP2021503559A JP2021503559A JPWO2020020790A5 JP WO2020020790 A5 JPWO2020020790 A5 JP WO2020020790A5 JP 2021503559 A JP2021503559 A JP 2021503559A JP 2021503559 A JP2021503559 A JP 2021503559A JP WO2020020790 A5 JPWO2020020790 A5 JP WO2020020790A5
- Authority
- JP
- Japan
- Prior art keywords
- release system
- osmotic release
- weight
- core
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003204 osmotic effect Effects 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 201000007917 background diabetic retinopathy Diseases 0.000 claims description 6
- 208000020832 chronic kidney disease Diseases 0.000 claims description 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000009424 thromboembolic effect Effects 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- PPZZCMKWRAVJDS-UHFFFAOYSA-N 3-cyclopropylpropanoic acid Chemical compound OC(=O)CCC1CC1 PPZZCMKWRAVJDS-UHFFFAOYSA-N 0.000 claims description 2
- 201000006306 Cor pulmonale Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229960004676 antithrombotic agent Drugs 0.000 claims description 2
- -1 antithrombotics Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000002664 nootropic agent Substances 0.000 claims description 2
- 230000001777 nootropic effect Effects 0.000 claims description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185135.3 | 2018-07-24 | ||
| EP18185135 | 2018-07-24 | ||
| PCT/EP2019/069564 WO2020020790A1 (de) | 2018-07-24 | 2019-07-19 | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531297A JP2021531297A (ja) | 2021-11-18 |
| JP2021531297A5 JP2021531297A5 (https=) | 2022-07-26 |
| JPWO2020020790A5 true JPWO2020020790A5 (https=) | 2022-07-26 |
Family
ID=63041848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503559A Pending JP2021531297A (ja) | 2018-07-24 | 2019-07-19 | 経口投与可能であり、修飾された放出を有する薬学的投薬形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210283046A1 (https=) |
| EP (1) | EP3826619A1 (https=) |
| JP (1) | JP2021531297A (https=) |
| CN (1) | CN112469398A (https=) |
| CA (1) | CA3107174A1 (https=) |
| WO (1) | WO2020020790A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| WO2023284724A1 (zh) * | 2021-07-12 | 2023-01-19 | 上海博志研新药物技术有限公司 | 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| ES2039287T3 (es) | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
| US4892739A (en) * | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
| DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AR053986A1 (es) * | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| CN100563637C (zh) * | 2006-10-13 | 2009-12-02 | 北京红林制药有限公司 | 一种控释给药的药芯组合物和控释制剂及其制备方法 |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| CA3039735A1 (en) * | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
-
2019
- 2019-07-19 JP JP2021503559A patent/JP2021531297A/ja active Pending
- 2019-07-19 CA CA3107174A patent/CA3107174A1/en active Pending
- 2019-07-19 WO PCT/EP2019/069564 patent/WO2020020790A1/de not_active Ceased
- 2019-07-19 EP EP19740581.4A patent/EP3826619A1/de not_active Withdrawn
- 2019-07-19 CN CN201980048634.5A patent/CN112469398A/zh active Pending
- 2019-07-19 US US17/262,491 patent/US20210283046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102695130B1 (ko) | 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도 | |
| JP5658172B2 (ja) | アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法 | |
| CA2654054C (en) | Pharmaceutical composition comprising amlodipine and losartan | |
| US11759428B2 (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate | |
| EP2085076B1 (en) | Pharmaceutical composition in the form of coated microspheres for the modified release of a muscle relaxant and an nsaid | |
| JP2004505886A (ja) | 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤 | |
| KR20110081316A (ko) | 디아세레인 함유 약제학적 조성물 | |
| CN102348455A (zh) | 药物剂型的活性包衣 | |
| JP3017040B2 (ja) | トリメタジジンの経口投与用持続的放出型薬剤組成物 | |
| JP2021531297A5 (https=) | ||
| JP2021532113A5 (https=) | ||
| US20100008987A1 (en) | Modified Release Pharmaceutical Composition of Bupropion Hydrochloride | |
| JP2013523757A (ja) | マジンドールの製剤 | |
| JPWO2020020790A5 (https=) | ||
| KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
| KR20150111686A (ko) | 산화안정성이 향상된 텔미사르탄 및 (ｓ)-암로디핀을 포함하는 약제학적 제제 | |
| JPWO2020020789A5 (https=) | ||
| CA3210689A1 (en) | Fixed-dose pharmaceutical compositions | |
| KR20150068730A (ko) | 메트포르민 및 로자탄을 포함하는 이층정 복합 제제 | |
| KR20170076609A (ko) | 텔미사르탄 및 암로디핀을 함유한 약제학적 조성물 | |
| KR20090107960A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| KR20190107838A (ko) | 이바브라딘의 서방성 약제학적 조성물 및 이의 제조방법 | |
| CN115715184A (zh) | 替格瑞洛口服剂型及其制备方法 | |
| RU2021128594A (ru) | Фармацевтическая композиция, содержащая эзомепразол или его фармацевтически приемлемую соль и имеющая профиль двойного высвобождения |